Phibro(US:PAHC)2026-02-04 21:16Financial Performance - Net sales for the three months ended December 31, 2025, were $373.9 million, representing a 21% increase from $309.3 million in the same period of 2024[123]. - Gross profit for the six months ended December 31, 2025, was $252.4 million, a 36% increase compared to $185.4 million in the prior year[123]. - Operating income for the three months ended December 31, 2025, was $50.3 million, a 97% increase from $25.5 million in the same period of 2024[123]. - Net income for the six months ended December 31, 2025, was $54.0 million, significantly up from $10.2 million in the prior year[123]. - Adjusted EBITDA for the three months ended December 31, 2025, was $68.1 million, a 41% increase from $48.2 million in the same period of 2024[127]. - Gross profit for the three months ended December 31, 2025, was $132.7 million, reflecting a 30% increase compared to the prior year, with a gross margin of 35.5%[134]. - For the six months ended December 31, 2025, net sales were $737.8 million, an increase of $168.1 million or 30% compared to the same period in 2024[144]. - The Animal Health segment's net sales for the six months ended December 31, 2025, increased by $161.5 million or 39%, largely due to incremental revenues from the MFA portfolio[145]. - Net income for the three months ended December 31, 2025, was $27.5 million, an increase of $24.3 million compared to $3.2 million in the same period of 2024[143]. - Adjusted net income for the six months ended December 31, 2025, was $65.6 million, an increase of $29.2 million, or 80%, compared to $36.3 million in 2024[162]. Tax and Expenses - The effective tax rate for the three months ended December 31, 2025, was 24.6%, down from 34.2% in the same period of 2024[123]. - Selling, general and administrative (SG&A) expenses rose to $150.9 million, an increase of $8.7 million, or 6%, compared to the six months ended December 31, 2024[152]. - SG&A expenses for the three months ended December 31, 2025, were $82.3 million, an increase of $6.0 million or 8% compared to the same period in 2024[136]. - Interest expense for the three months ended December 31, 2025, was $11.8 million, an increase of $2.8 million due to higher average debt levels associated with the acquisition financing[138]. - Interest expense increased by $7.2 million, or 43%, to $23.8 million for the six months ended December 31, 2025, due to higher average debt levels[154]. Cash Flow and Investments - For the six months ended December 31, 2025, operating activities provided $28.7 million in net cash, an increase from $15.7 million in the same period of 2024, reflecting a change of $12.9 million[169]. - Cash used in investing activities was $38.2 million, with capital expenditures amounting to $24.9 million aimed at expanding production capacity and productivity improvements[170]. - Financing activities resulted in a cash outflow of $2.6 million, including $9.7 million paid in dividends and $8.1 million in scheduled principal payments on long-term debt[171]. - As of December 31, 2025, cash and cash equivalents and short-term investments totaled $74.5 million, down from $77.0 million as of June 30, 2025[173]. - The working capital increased to $525.9 million, compared to $456.3 million as of June 30, 2025, indicating improved liquidity[173]. - The ratio of current assets to current liabilities improved to 3.01:1 from 2.65:1, reflecting stronger short-term financial health[173]. Acquisitions and Market Performance - The acquisition of Zoetis's medicated feed additive portfolio contributed $382.8 million to overall net sales since completion, with $94.1 million recorded in Q4 2025[108]. - Animal Health segment net sales increased by $60.6 million or 26%, driven by a $51.8 million increase in MFAs and other products due to incremental revenues from the MFA portfolio acquired on October 31, 2024[130]. - Sales of the Mecadox product (carbadox) for the twelve months ended December 31, 2025, were approximately $22 million[120]. Risks and Challenges - Forward-looking statements indicate potential risks including economic downturns and regulatory changes that could impact future performance[188]. - The company faces significant risks from political and social instability, including armed conflicts and terrorist activities, which could impact operations[42]. - There is a reliance on the successful implementation of strategic initiatives and the continued operation of manufacturing facilities[42]. - The company is exposed to adverse economic market conditions, including currency fluctuations, which may affect profitability[42]. - The integration of acquired businesses, particularly the medicated feed additive product portfolio from Zoetis Inc., poses challenges[42]. - The company has a substantial level of indebtedness, which includes significant debt-service obligations[42]. - Market risks related to interest rates and foreign currency exchange rates are monitored, with hedging strategies in place[193]. - The company does not hedge exposure to market risks in a way that eliminates the effects of changing market conditions on earnings[193]. - There are ongoing risks related to data security breaches and cybersecurity attacks that could impact operations[42]. - The company is dependent on sophisticated information technology and infrastructure for its operations[42]. - Future earnings and cash flows are subject to uncertainty due to market risks and economic conditions[194].